A new report from calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.
A new report from the National Academy of Sciences, Engineering, and Medicine calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.
The report, “Making Medicines Affordable: A National Imperative,” recommends that steps be taken to address market failures that are “currently permeating” the biopharmaceutical sector: a lack of competition due to distortions in the application of patent protections; the imbalance between the negotiating power of suppliers and purchasers; and the convoluted structure of the supply chain. The report seeks methods to improve the affordability of prescription drugs without discouraging the development of new and more effective drugs for the future.
Among the report’s recommendations are the following:
The report was written by a panel of physicians, attorneys, economists, and former corporate leaders and insurance and pharmaceutical company executives who worked together to produce the independent, objective analysis. Two members of the panel filed dissenting views, as did pharma industry group Pharmaceutical Research and Manufacturers of America (PhRMA), which called the report a rehash of outdated ideas that would severely restrict patient access to innovative treatment.
The report acknowledges the biopharmaceutical sector’s success over the past several decades in developing and delivering effective drugs for improving health, combatting disease, and helping to make many health conditions previously thought to be untreatable now manageable or cured. But it decried the high and increasing costs of prescription drugs, coupled with broader trends in overall healthcare expenditures as unsustainable to society as a whole. “There is a critical need for policy changes that will ensure the availability and affordability of medicines for patients who need them,” the report notes. “There is little value in new drugs that patients cannot afford—and there is no value in drugs that do not exist. Thus, there is a fundamental tension between ensuring the availability of new drugs in the future and ensuring the affordability of those drugs that exist today.”
The report details the factors that increase the cost of drugs for patients, including:
The report also said that patients’ share of drug costs should be calculated as a fraction of the net purchase price of drugs, after rebates and discounts, rather than from list prices, to help reduce the financial burden on patients who need costly pharmaceuticals. In addition, the Justice Department and FTC should discourage direct-to-consumer advertising of prescription drugs, said the report, and discourage direct financial incentives for patients. The agencies should make sure that tax credits and incentives for development of drugs for rare diseases not be extended to widely sold drugs, and should further restrict drug company sales representatives from visiting physicians and providing free samples and other inducements.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.